Početna stranicaAMGN34 • BVMF
add
Amgen Inc. BDR
Preth. zaklj. cijena
52,95 R$
Dnevni raspon
52,95 R$ - 53,35 R$
Godišnji raspon
51,81 R$ - 73,92 R$
Tržišna kapitalizacija
148,80 mlr. USD
Prosječna količina
359,00
P/E omjer
-
Prinos dividende
-
U vijestima
Yahoo Finance
prije 1 dan
Amgen Inc (AMGN) Releases Top-Line Results From ASCEND Study of Rocatinlimab
2,24 %
1,33 %
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (USD) | lip 2025.info | Godišnja promjena |
|---|---|---|
Prihod | 9,18 mlr. | 9,43 % |
Operativni troškovi | 3,50 mlr. | 12,82 % |
Neto dohodak | 1,43 mlr. | 91,96 % |
Neto profitabilnost | 15,60 | 75,48 % |
Zarada po dionici | 6,02 | 21,13 % |
EBITDA | 4,34 mlr. | 5,79 % |
Efektivna porezna stopa | 8,67 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (USD) | lip 2025.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 8,03 mlr. | −13,69 % |
Ukupna imovina | 87,90 mlr. | −3,31 % |
Ukupne obveze | 80,47 mlr. | −5,31 % |
Ukupni kapital | 7,43 mlr. | — |
Dionice u optjecaju | 538,36 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 3,84 | — |
Povrat imovine | 8,47 % | — |
Povrat kapitala | 11,81 % | — |
Tok novca
Neto promjena novca
| (USD) | lip 2025.info | Godišnja promjena |
|---|---|---|
Neto dohodak | 1,43 mlr. | 91,96 % |
Gotovina od poslovanja | 2,28 mlr. | −7,28 % |
Gotovina iz ulaganja | −389,00 mil. | −79,26 % |
Gotovina iz financiranja | −2,67 mlr. | −0,91 % |
Neto promjena novca | −782,00 mil. | −92,14 % |
Slobodan tok novca | 220,75 mil. | −92,64 % |
Više
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health.
The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000. Wikipedia
Glavni izvršni direktor
Osnovano
8. tra 1980.
Web-lokacija
Zaposlenici
28.000
